{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:19:27Z","timestamp":1793366367065,"version":"4.5.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute, City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22\\u20131\\u20130331"],"award-info":[{"award-number":["W81XWH-22\\u20131\\u20130331"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425\\u201325\\u20131\\u20130500"],"award-info":[{"award-number":["HT9425\\u201325\\u20131\\u20130500"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.critrevonc.2026.105177","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:58:44Z","timestamp":1770134324000},"page":"105177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Emerging trends and treatment strategies in ovarian cancer: A comprehensive review"],"prefix":"10.1016","volume":"220","author":[{"given":"B. Madhu","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Ramisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41366-020-0523-9","article-title":"Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register","volume":"44","author":"Aarestrup","year":"2020","journal-title":"Int J. Obes."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105177_bib2","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1200\/JCO.2011.41.0183","article-title":"Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study","volume":"30","author":"Agudo","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib4","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","article-title":"Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients","volume":"10","author":"Alba-Bernal","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105177_bib6","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061470","article-title":"An overview of candidate therapeutic target genes in ovarian cancer","volume":"12","author":"Alexandrova","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/modpathol.3800057","article-title":"Molecular characterization of uterine clear cell carcinoma","volume":"17","author":"An","year":"2004","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-21-2599","article-title":"U.S. FDA drug approvals for gynecological malignancies: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib11","first-page":"49","article-title":"Can we prevent ovarian cancer?","volume":"85","author":"Aus","year":"2020","journal-title":"Ceska Gynekol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105177_bib13","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1158\/1078-0432.CCR-16-1119","article-title":"Racial\/ethnic disparities in ovarian cancer treatment and survival","volume":"22","author":"Bandera","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105177_bib15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(12)70322-4","article-title":"Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies","volume":"13","author":"Beral","year":"2012","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib16","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/IGC.0000000000001317","article-title":"Endometriosis-associated ovarian cancer: population characteristics and prognosis","volume":"28","author":"Barreta","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib17","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"Berek","year":"1983","journal-title":"Obstet. Gynecol."},{"issue":"224","key":"10.1016\/j.critrevonc.2026.105177_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105177_bib19","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105177_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.12.006","article-title":"Ovarian carcinosarcoma: Current developments and future perspectives","volume":"134","author":"Boussios","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1210\/en.2018-00794","article-title":"Epithelial mutations in endometriosis: link to ovarian cancer","volume":"160","author":"Bulun","year":"2019","journal-title":"Endocrinology"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105177_bib23","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105177_bib24","article-title":"Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology\/Gynecologic Oncology Group (GOG) study","volume":"36","author":"Burger","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7353","key":"10.1016\/j.critrevonc.2026.105177_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105177_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10214","key":"10.1016\/j.critrevonc.2026.105177_bib30","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJMcp0901926","article-title":"Clinical practice. Screening for ovarian cancer","volume":"361","author":"Clarke-Pearson","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105177_bib32","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"10106","key":"10.1016\/j.critrevonc.2026.105177_bib33","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105177_bib34","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An Overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11596-021-2462-7","article-title":"Adjuvant chemotherapy may not be necessary for women with stage IC1 epithelial ovarian cancer","volume":"42","author":"Deng","year":"2022","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105177_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.critrevonc.2017.10.005","article-title":"Fertility management for malignant ovarian germ cell tumors patients","volume":"120","author":"Di Tucci","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ijc.25050","article-title":"Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition","volume":"127","author":"Dossus","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib40","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105177_bib41","article-title":"Randomized controlled phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer \u2013 AGO DESKTOP III\/ENGOT ov20","volume":"78","author":"Dubois","year":"2017","journal-title":"Geburtshilfe und Frauenheilkd."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105177_bib42","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105177_bib43","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105177_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102351","article-title":"Targeting Wnt signaling in endometrial cancer","volume":"13","author":"Fatima","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8899","key":"10.1016\/j.critrevonc.2026.105177_bib45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.31063","article-title":"Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study","volume":"142","author":"Gaitskell","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105177_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2013.06.034","article-title":"Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome","volume":"131","author":"George","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2021.10.080","article-title":"Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis","volume":"164","author":"Goldberg","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"9Pt2","key":"10.1016\/j.critrevonc.2026.105177_bib50","first-page":"3771","article-title":"Effect of diet on excretion of estrogens in pre- and postmenopausal women","volume":"41","author":"Goldin","year":"1981","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105177_bib51","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib52","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ijc.23108","article-title":"Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer","volume":"122","author":"Gram","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105177_bib54","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/ijc.26235","article-title":"Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study","volume":"130","author":"Gram","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.07.008","article-title":"State of the Science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer","volume":"138","author":"Graybill","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/humupd\/dmm012","article-title":"Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Greiser","year":"2007","journal-title":"Hum. Reprod. Update"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju146","article-title":"Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis","volume":"106","author":"Guan","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/bcr788","article-title":"Tavassoli FA, Devilee P: Pathology and genetics: tumors of the breast and female genital organs. WHO classification of tumors series - volume IV. Lyon, France: IARC Press","volume":"6","author":"Hanby","year":"2004","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib59","first-page":"227","article-title":"Institution-based cancer incidence in a local population in Pakistan: nine-year data analysis","volume":"10","author":"Hanif","year":"2009","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib60","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105177_bib62","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib63","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0029-7844(97)00118-X","article-title":"Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study","volume":"89","author":"Hempling","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2026.105177_bib64","unstructured":"Herrington, C.S., 2014. Muir's textbook of pathology, 15th ed ed. CRC Press\/Taylor & Francis Group, Boca Raton."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105177_bib65","article-title":"ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)","volume":"41","author":"Herzog","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5152\/dir.2015.34414","article-title":"Sex cord-stromal tumors of the ovary: a comprehensive review and update for radiologists","volume":"21","author":"Horta","year":"2015","journal-title":"Diagn. Inter. Radio."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib67","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2022.09.004","article-title":"Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer","volume":"167","author":"Hou","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000369","article-title":"Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","volume":"39","author":"Howitt","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105177_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1755-8794-5-47","article-title":"Histotype-specific copy-number alterations in ovarian cancer","volume":"5","author":"Huang","year":"2012","journal-title":"BMC Med Genom."},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105177_bib70","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumors identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib72","first-page":"142","article-title":"Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women","volume":"85","author":"John","year":"1993","journal-title":"Collab. Ovarian Cancer Group. J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105177_bib73","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"issue":"9698","key":"10.1016\/j.critrevonc.2026.105177_bib74","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib75","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.21873\/invivo.12667","volume":"35","author":"Kim","year":"2021","journal-title":"Vivo"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","article-title":"The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma","volume":"123","author":"King","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib77","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicenter, open-label, randomized, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105177_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/934261","article-title":"Recent concepts of ovarian carcinogenesis: type I and type II","volume":"2014","author":"Koshiyama","year":"2014","journal-title":"Biomed. Res Int"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib80","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early-stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105177_bib81","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"Kustanovich","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CEJ.0000000000000217","article-title":"Ovarian cancer: epidemiology and risk factors","volume":"26","author":"La Vecchia","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2026.105177_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004706.pub5","article-title":"Adjuvant (post-surgery) chemotherapy for early-stage epithelial ovarian cancer","author":"Lawrie","year":"2015","journal-title":"Cochrane Database Syst. Rev. 2015(12) CD004706"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib84","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cam4.590","article-title":"Epithelial ovarian cancer subtypes attributable to smoking in the Norwegian Women and Cancer Study, 2012","volume":"5","author":"Licaj","year":"2016","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105177_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710078","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers","volume":"23","author":"Lim","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib87","first-page":"1107","article-title":"The association between overweight, obesity and ovarian cancer: a meta-analysis","volume":"45(","author":"Liu","year":"2015","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105177_bib88","doi-asserted-by":"crossref","first-page":"S1268","DOI":"10.1016\/j.annonc.2023.10.020","article-title":"LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients","volume":"34","author":"Lonardi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib89","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10689-013-9664-5","article-title":"Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention","volume":"12","author":"Lu","year":"2013","journal-title":"Fam. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib91","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e12","article-title":"Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis","volume":"31","author":"Lv","year":"2020","journal-title":"J. Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","article-title":"Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management","volume":"3","author":"Lynch","year":"2009","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib93","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5","article-title":"Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review","volume":"78","author":"Lynch","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105177_bib94","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S155425","article-title":"First-line treatment of women with advanced ovarian cancer: focus on bevacizumab","volume":"12","author":"Marchetti","year":"2019","journal-title":"Oncol. Targets Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib95","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib96","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib98","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.pgp.0000139644.38835.9d","article-title":"An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type","volume":"23","author":"McCluggage","year":"2004","journal-title":"Int J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13029","article-title":"Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis","volume":"54","author":"Mei","year":"2021","journal-title":"Cell Prolif."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105177_bib101","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105177_bib102","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.annepidem.2016.07.004","article-title":"Reproductive factors and ovarian cancer risk in African American women","volume":"26","author":"Moorman","year":"2016","journal-title":"Ann. Epidemiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib103","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/aje\/kwp176","article-title":"Ovarian cancer risk factors in African American and white women","volume":"170","author":"Moorman","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib104","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jama.2009.1052","article-title":"Hormone therapy and ovarian cancer","volume":"302","author":"Morch","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.05.008","article-title":"Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses","volume":"150","author":"Mueller","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib106","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib107","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0032-1328658","article-title":"Small cell ovarian carcinomas - characterization of two rare tumor entities","volume":"73","author":"Munstedt","year":"2013","journal-title":"Geburtshilfe Frau"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10020077","article-title":"Ovarian seromucinous tumors: pathogenesis, morphologic spectrum, and clinical issues","volume":"10","author":"Nagamine","year":"2020","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib109","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200225","article-title":"Intraperitoneal carboplatin for ovarian cancer - a phase 2\/3 trial","volume":"2","author":"Nagao","year":"2023","journal-title":"NEJM Evid."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib110","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3892\/mco.2014.397","article-title":"Features of ovarian cancer in Lynch syndrome (Review)","volume":"2","author":"Nakamura","year":"2014","journal-title":"Mol. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib111","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0959-8049(02)00743-8","article-title":"Family history of cancer and risk of ovarian cancer","volume":"39","author":"Negri","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib112","first-page":"176","article-title":"Racial differences in ovarian cancer risk","volume":"92","author":"Ness","year":"2000","journal-title":"J. Natl. Med Assoc."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib113","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/IGC.0000000000000100","article-title":"The link between endometriosis and ovarian cancer: clinical implications","volume":"24","author":"Nezhat","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/1097-0142(19940715)74:2<545::AID-CNCR2820740204>3.0.CO;2-Q","article-title":"Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention","volume":"74","author":"Nguyen","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105177_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637675","article-title":"The role of tumor-stroma interactions in drug resistance within tumor microenvironment","volume":"9","author":"Ni","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib117","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105177_bib118","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomized trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105177_bib119","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17305\/bjbms.2013.2371","article-title":"Hormonal risk factors for ovarian cancer in the Albanian case-control study","volume":"13","author":"Pajenga","year":"2013","journal-title":"Bosn. J. Basic Med Sci."},{"key":"10.1016\/j.critrevonc.2026.105177_bib121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejro.2015.01.001","article-title":"CT features of low-grade serous carcinoma of the ovary","volume":"2","author":"Pannu","year":"2015","journal-title":"Eur. J. Radio. Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib122","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib123","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/oxfordjournals.aje.a116199","article-title":"Family history of reproductive cancers and ovarian cancer risk: an Italian case-control study","volume":"135","author":"Parazzini","year":"1992","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumor DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLOS Med."},{"issue":"7553","key":"10.1016\/j.critrevonc.2026.105177_bib125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib126","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.23956","article-title":"Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin","volume":"115","author":"Pearce","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ctrv.2008.02.002","article-title":"Germ cell tumors of the ovary","volume":"34","author":"Pectasides","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105177_bib129","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2016","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib132","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/ije\/dyx252","article-title":"Racial\/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies","volume":"47","author":"Peres","year":"2018","journal-title":"Int J. Epidemiol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105177_bib133","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2018-0070","article-title":"Avelumab (anti-PD-L1) in platinum-resistant\/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design","volume":"14","author":"Pujade-Lauraine","year":"2018","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib134","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.bjc.6690731","article-title":"Hormone replacement therapy and risk of epithelial ovarian cancer","volume":"81","author":"Purdie","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"9 3","key":"10.1016\/j.critrevonc.2026.105177_bib135","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/IGC.0000000000000249","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors","volume":"24","author":"Ray-Coquard","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Ray-Coquard","year":"2020","journal-title":"Int J. Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105177_bib137","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105177_bib138","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","article-title":"TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7)","volume":"29","author":"Reuss","year":"2019","journal-title":"Int J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105177_bib139","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/ijc.32635","article-title":"Adult dietary fat intake and ovarian cancer risk","volume":"146","author":"Rice","year":"2020","journal-title":"Int J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.soncn.2019.02.009","article-title":"New and novel therapies for gynecologic cancers","volume":"35","author":"Richardson","year":"2019","journal-title":"Semin Oncol. Nurs."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib141","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju048","article-title":"Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples","volume":"106","author":"Riester","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122113","article-title":"Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment","volume":"17","author":"Rojas","year":"2016","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105177_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcsup.2020.02.001","article-title":"Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications","volume":"15","author":"Romero","year":"2020","journal-title":"EJC Suppl."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib144","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/jog.15955","article-title":"Extraovarian seromucinous borderline tumor: Case report and literature review","volume":"50","author":"Sakata","year":"2024","journal-title":"J. Obstet. Gynaecol. Res"},{"key":"10.1016\/j.critrevonc.2026.105177_bib145","first-page":"1","article-title":"Risk factors for epithelial ovarian carcinoma in india: a case control study in low-incidence population","volume":"12","author":"Santhanam","year":"2016","journal-title":"Int. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib146","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12885-020-07252-y","article-title":"Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study","volume":"20","author":"Schraa","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib147","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00404-013-2784-1","article-title":"Ovarian epithelial tumors and reproductive factors: a systematic review","volume":"287","author":"Schuler","year":"2013","journal-title":"Arch. Gynecol. Obstet."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105177_bib148","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JOP.2016.016261","article-title":"Ovarian sex cord-stromal tumors","volume":"12","author":"Schultz","year":"2016","journal-title":"J. Oncol. Pr."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib149","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/ijgc-2022-003348","article-title":"There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"32","author":"Schwameis","year":"2022","journal-title":"Int J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.5858\/2000-124-474-TOTOMG","article-title":"Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament","volume":"124","author":"Selvaggi","year":"2000","journal-title":"Arch. Pathol. Lab Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib151","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib152","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The origin of ovarian cancer species and precancerous landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib153","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib154","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ajcp\/93.4.457","article-title":"Ovarian carcinomas with transitional cell carcinoma patter","volume":"93","author":"Silva","year":"1990","journal-title":"N. Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00428-018-2504-0","article-title":"A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary","volume":"474","author":"Simons","year":"2019","journal-title":"Virchows Arch."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib156","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41379-019-0401-y","article-title":"Two types of primary mucinous ovarian tumors can be distinguished based on their origin","volume":"33","author":"Simons","year":"2020","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib157","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105177_bib158","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib159","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105177_bib160","first-page":"723","article-title":"Update on the role of surgery in the management of advanced epithelial ovarian cancer","volume":"18","author":"Straubhar","year":"2020","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105177_bib161","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib162","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1349-7006.2008.00988.x","article-title":"Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5\u2032-untranslated region in human epithelial ovarian carcinoma","volume":"99","author":"Suzuki","year":"2008","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib163","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajpath.2015.11.008","article-title":"Molecular genetic analysis of ovarian brenner tumors and associated mucinous epithelial neoplasms: high variant concordance and identification of mutually exclusive RAS driver mutations and MYC amplification","volume":"186","author":"Tafe","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib164","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/his.14399","article-title":"Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach","volume":"80","author":"Talia","year":"2022","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105177_bib165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/ijgc-2024-005313","article-title":"Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis","volume":"34","author":"Taliento","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031845","article-title":"Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements","volume":"25","author":"Tavares","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib167","article-title":"Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells","volume":"5","author":"Testa","year":"2018","journal-title":"Med. (Basel)"},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105177_bib168","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO Guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105177_bib169","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105177_bib170","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105177_bib171","first-page":"113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organization for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst","volume":"95","author":"Trimbos","year":"2003"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib172","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/aje\/kwg177","article-title":"Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study","volume":"158","author":"Tung","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib173","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jpn3.12395","article-title":"Response to FDA draft guidance on pediatric IBD drug approval trials: A consensus statement from the IBD Porto Group","volume":"80","author":"Turner","year":"2025","journal-title":"J. Pedia Gastroenterol. Nutr."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib174","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas ovarian study","volume":"35","author":"Vang","year":"2016","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105177_bib176","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv. Anat. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib177","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/1066896910387601","article-title":"Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications","volume":"19","author":"Vemavarapu","year":"2011","journal-title":"Int J. Surg. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105177_bib178","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105177_bib179","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105177_bib180","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105177_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19221","article-title":"Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105177_bib182","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancer depends on PIK3CB","volume":"105","author":"Wee","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105177_bib183","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib184","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0036-1597120","article-title":"Cancer implications for patients with endometriosis","volume":"35","author":"Wilbur","year":"2017","journal-title":"Semin Reprod. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105177_bib186","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105177_bib187","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105177_bib188","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/1055-9965.EPI-15-0023","article-title":"African americans and hispanics remain at lower risk of ovarian cancer than non-hispanic whites after considering nongenetic risk factors and oophorectomy rates","volume":"24","author":"Wu","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105177_bib189","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ijc.28701","article-title":"Epigenetic determinants of ovarian clear cell carcinoma biology","volume":"135","author":"Yamaguchi","year":"2014","journal-title":"Int J. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105177_bib190","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/aje\/kwv308","article-title":"Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women","volume":"183","author":"Yang","year":"2016","journal-title":"Am. J. Epidemiol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105177_bib191","first-page":"5107","article-title":"Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer","volume":"51","author":"Yee","year":"1991","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105177_bib192","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJMcpc1000272","article-title":"Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass","volume":"362","author":"Young","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105177_bib193","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:24:59Z","timestamp":1778581499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":193,"alternative-id":["S1040842826000648"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105177","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging trends and treatment strategies in ovarian cancer: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105177"}}